ruxolitinib
The phase Ib clinical trial is being launched by Cellenkos in partnership with Incyte as part of their LIMBER initiative.
Long-term results from the RESPONSE-2 trial confirm efficacy of ruxolitinib for PV.
The REFINE trial observed clinically meaningful splenic responses with navitoclax plus ruxolitinib.
Advertisement
This phase II study enrolled 34 adult patients with intermediate- to high-risk myelofibrosis.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.